{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T14:17:49Z","timestamp":1788185869421,"version":"build-2803163510"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T00:00:00Z","timestamp":1779235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T00:00:00Z","timestamp":1779235200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s12185-026-04224-z","type":"journal-article","created":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T10:19:23Z","timestamp":1779272363000},"page":"422-428","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Effectiveness and tolerability of switching from 20% subcutaneous immunoglobulin to hyaluronidase-facilitated subcutaneous immunoglobulin 10% in the same patients with secondary hypogammaglobulinemia"],"prefix":"10.1007","volume":"124","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3374-9814","authenticated-orcid":false,"given":"Yoshinori","family":"Hashimoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saaya","family":"Hosoda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiromi","family":"Omura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,20]]},"reference":[{"key":"4224_CR1","doi-asserted-by":"publisher","first-page":"33","DOI":"10.3389\/fimmu.2019.00033","volume":"10","author":"SY Patel","year":"2019","unstructured":"Patel SY, Carbone J, Jolles S. The expanding field of secondary antibody deficiency: causes, diagnosis, and management. Front Immunol. 2019;10:33.","journal-title":"Front Immunol"},{"issue":"1","key":"4224_CR2","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.clim.2010.06.012","volume":"137","author":"JS Orange","year":"2010","unstructured":"Orange JS, Grossman WJ, Navickis RJ, Wilkes MM. Impact of trough IgG on pneumonia incidence in primary immunodeficiency: a meta-analysis of clinical studies. Clin Immunol. 2010;137(1):21\u201330.","journal-title":"Clin Immunol"},{"issue":"4","key":"4224_CR3","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.medcli.2023.10.005","volume":"162","author":"E Angarola","year":"2024","unstructured":"Angarola E, Peuchot VA, Warley F, Liberatore DI. Secondary hypogammaglobulinemia in adults-a large retrospective cohort study. Med\u00a0Clin (Barc). 2024;162(4):170\u20138.","journal-title":"Med\u00a0Clin (Barc)"},{"issue":"1","key":"4224_CR4","doi-asserted-by":"publisher","first-page":"274","DOI":"10.3390\/curroncol30010022","volume":"30","author":"A Visentin","year":"2022","unstructured":"Visentin A, Molinari MC, Pravato S, Cellini A, Angotzi F, Cavaretta CA, et al. A retrospective study on the efficacy of subcutaneous immunoglobulin as compared to intravenous formulation in patients with chronic lymphocytic leukemia and secondary antibody deficiency. Curr Oncol. 2022;30(1):274\u201383.","journal-title":"Curr Oncol"},{"issue":"42","key":"4224_CR5","doi-asserted-by":"publisher","first-page":"e45145","DOI":"10.1097\/MD.0000000000045145","volume":"104","author":"Y Hashimoto","year":"2025","unstructured":"Hashimoto Y, Hosoda S, Omura H, Tanaka T. Real-world evidence from Japan in patients with hematological malignancies and secondary hypogammaglobulinemia treated with 20% subcutaneous immunoglobulin, Ig20Gly: a retrospective cohort study. Medicine (Baltimore). 2025;104(42):e45145.","journal-title":"Medicine (Baltimore)"},{"issue":"1","key":"4224_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/cei\/uxac070","volume":"210","author":"S Grigoriadou","year":"2022","unstructured":"Grigoriadou S, Clubbe R, Garcez T, Huissoon A, Grosse-Kreul D, Jolles S, et al. British Society for Immunology and United Kingdom Primary Immunodeficiency Network (UKPIN) consensus guideline for the management of immunoglobulin replacement therapy. Clin Exp Immunol. 2022;210(1):1\u201313.","journal-title":"Clin Exp Immunol"},{"issue":"11-12","key":"4224_CR7","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1159\/000527655","volume":"107","author":"C von Achenbach","year":"2022","unstructured":"von Achenbach C, Hevia Hernandez G, von Gunten S. The choice between intravenous and subcutaneous immunoglobulins: aspects for consideration. Pharmacology. 2022;107(11\u201312):556\u201363.","journal-title":"Pharmacology"},{"issue":"2","key":"4224_CR8","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/S1081-1206(10)60197-4","volume":"101","author":"ML Moore","year":"2008","unstructured":"Moore ML, Quinn JM. Subcutaneous immunoglobulin replacement therapy for primary antibody deficiency: advancements into the 21st century. Ann Allergy Asthma Immunol. 2008;101(2):114\u201321.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"4","key":"4224_CR9","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1517\/17425247.4.4.427","volume":"4","author":"GI Frost","year":"2007","unstructured":"Frost GI. Recombinant human hyaluronidase (rHuPH20): an enabling platform for subcutaneous drug and fluid administration. Expert Opin Drug Deliv. 2007;4(4):427\u201340.","journal-title":"Expert Opin Drug Deliv"},{"issue":"5","key":"4224_CR10","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1208\/s12248-015-9782-0","volume":"17","author":"S Rosengren","year":"2015","unstructured":"Rosengren S, Dychter SS, Printz MA, Huang L, Schiff RI, Schwarz HP, et al. Clinical immunogenicity of rHuPH20, a hyaluronidase enabling subcutaneous drug administration. AAPS J. 2015;17(5):1144\u201356.","journal-title":"AAPS J"},{"issue":"4","key":"4224_CR11","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/j.jaci.2012.06.021","volume":"130","author":"RL Wasserman","year":"2012","unstructured":"Wasserman RL, Melamed I, Stein MR, Gupta S, Puck J, Engl W, et al. Recombinant human hyaluronidase-facilitated subcutaneous infusion of human immunoglobulins for primary immunodeficiency. J Allergy Clin Immunol. 2012;130(4):951-957e11.","journal-title":"J Allergy Clin Immunol"},{"issue":"10","key":"4224_CR12","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1080\/1750743X.2024.2354091","volume":"16","author":"PM Ellerbroek","year":"2024","unstructured":"Ellerbroek PM, Hanitsch LG, Witte T, Lougaris V, Hagen PMV, Paassen PV, et al. Long-term safety of hyaluronidase-facilitated subcutaneous immunoglobulin 10%: a European post-authorization study. Immunotherapy. 2024;16(10):679\u201391.","journal-title":"Immunotherapy"},{"issue":"8","key":"4224_CR13","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s10875-024-01769-8","volume":"44","author":"A Rubinstein","year":"2024","unstructured":"Rubinstein A, Mabudian M, McNeil D, Patel NC, Wasserman RL, Gupta S, et al. Long-term safety of facilitated subcutaneous immunoglobulin 10% treatment in US clinical practice in patients with primary immunodeficiency diseases: results from a post-authorization safety study. J Clin Immunol. 2024;44(8):181.","journal-title":"J Clin Immunol"},{"issue":"16","key":"4224_CR14","doi-asserted-by":"publisher","first-page":"1532367","DOI":"10.3389\/fimmu.2025.1532367","volume":"14","author":"S Mart\u00ednez Mercader","year":"2025","unstructured":"Mart\u00ednez Mercader S, Garcia-Bustos V, Moral Moral P, Mart\u00ednez Buenaventura C, Escudero Vergara E, Montaner Bosch MC, et al. Patient-centered outcomes with subcutaneous immunoglobulin use for infection control in primary and secondary immunodeficiencies: data of a GEIE Spanish Registry. Front Immunol. 2025;14(16):1532367.","journal-title":"Front Immunol"},{"issue":"1","key":"4224_CR15","doi-asserted-by":"publisher","first-page":"e0313694","DOI":"10.1371\/journal.pone.0313694","volume":"20","author":"G Lef\u00e8vre","year":"2025","unstructured":"Lef\u00e8vre G, Borget I, Lef\u00e8vre C, Maherzi C, Nucit A, Hennaoui M, et al. Healthcare resource utilization and costs in immunodeficient patients receiving subcutaneous Ig: real-world evidence from France. PLoS ONE. 2025;20(1):e0313694.","journal-title":"PLoS ONE"},{"issue":"4","key":"4224_CR16","doi-asserted-by":"publisher","first-page":"215","DOI":"10.2217\/imt-2021-0256","volume":"14","author":"RL Wasserman","year":"2022","unstructured":"Wasserman RL, Gupta S, Stein M, Rabbat CJ, Engl W, Leibl H, et al. Infection rates and tolerability of three different immunoglobulin administration modalities in patients with primary immunodeficiency diseases. Immunotherapy. 2022;14(4):215\u201324.","journal-title":"Immunotherapy"},{"key":"4224_CR17","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y. Investigation of the freely available easy-to-use software \u201cEZR\u201d for medical statistics. Bone Marrow Transplant. 2013;48:452\u20138.","journal-title":"Bone Marrow Transplant"},{"issue":"5","key":"4224_CR18","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1016\/j.jaci.2022.01.025","volume":"149","author":"IM Otani","year":"2022","unstructured":"Otani IM, Lehman HK, Jongco AM, Tsao LR, Azar AE, Tarrant TK, et al. Practical guidance for the diagnosis and management of secondary hypogammaglobulinemia: A work group report of the AAAAI primary immunodeficiency and altered immune response committees. J Allergy Clin Immunol. 2022;149(5):1525\u201360.","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"4224_CR19","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1111\/ejh.13580","volume":"106","author":"S Jolles","year":"2021","unstructured":"Jolles S, Michallet M, Agostini C, Albert MH, Edgar D, Ria R, et al. Treating secondary antibody deficiency in patients with haematological malignancy: European expert consensus. Eur J Haematol. 2021;106(4):439\u201349.","journal-title":"Eur J Haematol"},{"issue":"6","key":"4224_CR20","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1007\/s10875-016-0298-x","volume":"36","author":"RL Wasserman","year":"2016","unstructured":"Wasserman RL, Melamed I, Stein MR, Engl W, Sharkhawy M, Leibl H, et al. Long-term tolerability, safety, and efficacy of recombinant human hyaluronidase-facilitated subcutaneous infusion of human immunoglobulin for primary immunodeficiency. J Clin Immunol. 2016;36(6):571\u201382.","journal-title":"J Clin Immunol"},{"issue":"2","key":"4224_CR21","doi-asserted-by":"publisher","first-page":"131","DOI":"10.2217\/imt-2019-0175","volume":"12","author":"PV Paassen","year":"2020","unstructured":"Paassen PV, Pittrow D, Scheidegger C, Klotsche J, Ellerbroek PM. Use of recombinant human hyaluronidase-facilitated subcutaneous immunoglobulin in elderly patients. Immunotherapy. 2020;12(2):131\u20139.","journal-title":"Immunotherapy"},{"issue":"3","key":"4224_CR22","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1007\/s10238-020-00633-4","volume":"20","author":"F Angelotti","year":"2020","unstructured":"Angelotti F, Capecchi R, Giannini D, Mazzarella O, Rocchi V, Migliorini P. Long-term efficacy, safety, and tolerability of recombinant human hyaluronidase-facilitated subcutaneous infusion of immunoglobulin (Ig) (fSCIG; HyQvia(\u00ae)) in immunodeficiency diseases: real-life data from a monocentric experience. Clin Exp Med. 2020;20(3):387\u201392.","journal-title":"Clin Exp Med"},{"key":"4224_CR23","doi-asserted-by":"publisher","first-page":"670547","DOI":"10.3389\/fimmu.2021.670547","volume":"12","author":"NB Hustad","year":"2021","unstructured":"Hustad NB, Degerud HM, Hjelmerud I, Fraz MSA, Nord\u00f8y I, Tr\u00f8seid M, et al. Real-world experiences with facilitated subcutaneous immunoglobulin substitution in patients with hypogammaglobulinemia, using a three-step ramp-up schedule. Front Immunol. 2021;12:670547.","journal-title":"Front Immunol"},{"issue":"7","key":"4224_CR24","first-page":"4187","volume":"38","author":"M Dimou","year":"2018","unstructured":"Dimou M, Iliakis T, Maltezas D, Bitsani A, Kalyva S, Koudouna A, et al. Efficacy-safety of facilitated subcutaneous immunoglobulin in immunodeficiency due to hematological malignancies. A Single-Center Retrospective Analysis Anticancer Res. 2018;38(7):4187\u201391.","journal-title":"A Single-Center Retrospective Analysis Anticancer Res"},{"issue":"6","key":"4224_CR25","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1007\/s10875-023-01470-2","volume":"43","author":"M Borte","year":"2023","unstructured":"Borte M, Hanitsch LG, Mahlaoui N, Fasshauer M, Huscher D, Speletas M, et al. Facilitated subcutaneous immunoglobulin treatment in patients with immunodeficiencies: the FIGARO study. J Clin Immunol. 2023;43(6):1259\u201371.","journal-title":"J Clin Immunol"},{"issue":"18","key":"4224_CR26","doi-asserted-by":"publisher","first-page":"4524","DOI":"10.3390\/cancers15184524","volume":"15","author":"M Dimou","year":"2023","unstructured":"Dimou M, Speletas M, Milito C, Pyzik A, Huscher D, Kamieniak M, et al. Insights into facilitated subcutaneous immunoglobulin use in patients with secondary immunodeficiency diseases: a FIGARO subgroup analysis. Cancers (Basel). 2023;15(18):4524.","journal-title":"Cancers (Basel)"},{"key":"4224_CR27","unstructured":"EMA. Guideline on core SmPC for human normal immunoglobulin for intravenous administration (IVIg) \u2013 revision 6 2021 https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-core-smpc-human-normal-immunoglobulin-intravenous-administration-ivig-rev-6_en.pdf"},{"issue":"8","key":"4224_CR28","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1007\/s10875-024-01771-0","volume":"44","author":"E Yalcin Gungoren","year":"2024","unstructured":"Yalcin Gungoren E, Yorgun Altunbas M, Dikici U, Meric Z, Eser Simsek I, Kiykim A, et al. Insights into patient experiences with facilitated subcutaneous immunoglobulin therapy in primary immune deficiency: a prospective observational cohort. J Clin Immunol. 2024;44(8):169.","journal-title":"J Clin Immunol"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-026-04224-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-026-04224-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-026-04224-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T13:56:30Z","timestamp":1788184590000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-026-04224-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,20]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["4224"],"URL":"https:\/\/doi.org\/10.1007\/s12185-026-04224-z","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,20]]},"assertion":[{"value":"27 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no conflicts of interest.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}